Vera Therapeutics (VERA) Research & Development (2020 - 2026)
Vera Therapeutics' (VERA) quarterly Research & Development came in at $86.0 million in Q1 2026, up 108.37% YoY from $41.3 million in Q1 2025, and up 45.02% on a QoQ basis from $59.3 million in Q4 2025.
Vera Therapeutics (VERA) Research & Development (2020 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 7 years of Research & Development data on file, last reported at $86.0 million in Q1 2026.
- Quarterly Research & Development rose 108.37% year-over-year to $86.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $260.0 million (up 80.24% YoY) and the FY2025 annual result came in at $215.3 million, up 70.61% from the prior year.
- Research & Development climbed to $86.0 million in Q1 2026, from $59.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $86.0 million in Q1 2026 to a low of $3.7 million in Q3 2022.
- A 5-year average of $35.1 million and a median of $29.3 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 2490.81% — and 2023, when it slumped 68.17%.
- Tracing VERA's Research & Development over 5 years: stood at $65.3 million in 2022, then tumbled by 68.17% to $20.8 million in 2023, then soared by 60.44% to $33.3 million in 2024, then jumped by 77.86% to $59.3 million in 2025, then soared by 45.02% to $86.0 million in 2026.
- The last three Research & Development figures came in at $86.0 million (Q1 2026), $59.3 million (Q4 2025), and $56.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - | 60.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.08 Mn |
| Mar 31, 2026 | 86.01 Mn |
| Dec 31, 2025 | 59.31 Mn |
| Sep 30, 2025 | 56.47 Mn |
| Jun 30, 2025 | 58.20 Mn |
| Mar 31, 2025 | 41.28 Mn |
| Dec 31, 2024 | 33.35 Mn |
| Sep 30, 2024 | 40.31 Mn |
| Jun 30, 2024 | 29.31 Mn |
| Mar 31, 2024 | 23.20 Mn |
| Dec 31, 2023 | 20.79 Mn |
| Sep 30, 2023 | 16.10 Mn |
| Jun 30, 2023 | 16.23 Mn |
| Mar 31, 2023 | 25.11 Mn |
| Dec 31, 2022 | 65.29 Mn |
| Sep 30, 2022 | 3.70 Mn |
| Jun 30, 2022 | 10.11 Mn |
| Mar 31, 2022 | 12.55 Mn |
| Dec 31, 2021 | -2.73 Mn |
| Sep 30, 2021 | 3.56 Mn |